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Chapter 1: Overview 
_______________________________________________________________________  
1.1 Overview 
 
The goal of this community-based randomized clinical trial is to test hypotheses about the 
impact on trachoma and ocular C. trachomatis infection of varying frequency and coverage of mass 
azithromycin use in communities. This trial will add to the evidence base to improve the 
implementation of the antibiotic component of the SAFE (Surgery/Antibiotics/ Face 
washing/Environmental change) strategy for trachoma control. Through the PRET partnership, we 
will address significant trachoma program barriers: slow decline in trachoma in these communities 
and re-emergence of infection following mass treatment.  
The overall objective is to determine optimal strategies for elimination of trachoma and 
infection under differing mass treatment coverages.  Specific objectives to meet this overall objective 
include:  
 
 To determine the effective coverage (80% to 90% versus above 90% in children) of mass 
azithromycin treatment necessary for hyperendemic areas that will lead to rapid reduction of 
infection to less than 5%.  
 
 To determine if mass azithromycin administration every six months in children can reduce 
infection in the entire community, and would be an effective control strategy in practice. In 
other words, do children act as a core group in the transmission of trachoma?   
 
To meet the overall objective, then, we have two major activities: (1) Conduct clinical trials 
of communities in Niger of alternative coverages and frequencies of administration of mass 
antibiotic treatment; (2) Determine the cost-effectiveness of these different strategies from program 
perspective.  
 
1.2 Research Questions 
 
1) COVERAGE: What are the differences at three years post-baseline in rates of trachoma and ocular C. 
trachomatis infection in villages randomized to mass antibiotic coverage of 80% to 89% (as measured in children ages 
less than 10 years) compared to villages randomized to enhanced coverage of 90% or greater?  
 
2) FREQUENCY OF MASS TREATMENT: What are the differences at three years post-baseline in rates of 
trachoma and ocular C. trachomatis infection in hyper-endemic villages in Niger randomized to mass treatment of 
children ages twelve and under biannually (every six months) compared to yearly mass treatment of everyone?  
 
Chapter 
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1.3 Overall Design 
 
We propose a community-randomized design within Niger which considers hyperendemicity 
to address questions of coverage and frequency. Within these study areas, communities will be 
randomized to two different coverage targets (80%-89% versus ≥90%) for three years of mass 
treatment. We will further randomize communities to annual mass azithromycin distribution versus 
every 6-month distribution. Only children ages 12 and under will receive azithromycin treatment.  
We will evaluate the efficacy of guiding further mass treatment according to a laboratory test for 
Chlamydia or WHO guidelines.  
 
Sentinel children randomly selected as cross sectional samples in these communities will be 
monitored at baseline, 6, 12, 18, 24, 30, and 36 months for infection and clinical disease. The three-
year study is in accord with the WHO guidelines for three years of mass treatment followed by a re-
survey to determine areas in need of further treatment.  
 
Primary analyses will focus on the comparison at three years of trachoma and infection rates 
in villages randomized to 90% or greater coverage versus less than 90%, and in villages randomized 
to yearly treatment of everyone versus 6 monthly treatment of children.  Primary analyses will 
consider the 2 X 2 factorial design, the baseline prevalence, and baseline indicators of environmental 
hygiene as co-variates and effect modifiers. Secondary analyses will evaluate trachoma and infection 
in children, adjusting for clustering at the village level.  
 
There are two ancillary studies nested within the trial. First, we will determine the cost-
effectiveness of the different treatment coverage and administration frequency arms. The data on 
costs associated with a lab-based strategy to guide mass treatment cessation will assist in 
development of the cost of such a tool if it is finally developed. Moreover, we must weigh the 
potential additional costs associated with treatments every six months for children, or higher 
coverage in villages, against the benefit in terms of reduction of trachoma infection.  
 
The second study will determine rates of re-emergence and the effect of multiple rounds of 
mass treatment within children. In communities selected at random within each arm, we will follow 
all children ages 9 years and under longitudinally after mass treatment for re-emergent trachoma 
infection and clinical disease. We will determine risk factors predicting re-emergence.  
 
These studies provide significant value to the trial in helping elucidate treatment “failures”, 
in providing cost-effectiveness data, as well as effectiveness data, on the treatment strategy 
alternatives.    
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Chapter 2: Background and Significance 
_____________________________________________________________ 
 
2.1 Trachoma as a Public Health Problem 
 
Trachoma, caused by ocular Chlamydia trachomatis, is the leading infectious cause of blindness 
worldwide. There are profound inequalities in the burden of trachoma, as it affects almost 
exclusively the poorest countries in the world, as measured by World Bank PovCal indices. Within 
affected countries, the geographic burden of trachoma is highest in relatively rural, poor regions. 
Research has shown that within these regions, trachoma disproportionately affects the most poor, 
and those who traditionally have no voice in leadership: the pool of trachoma in these impoverished 
communities is greatest in children less than five years of age, and women develop blindness from 
trachoma at a rate 2–3 times that of men.  
 
In addition to the heavy personal and societal burden inflicted by loss of vision, there are 
significant economic impacts as well. The 3.8 million cases of blindness and 5.3 million cases of low 
vision due to trachoma are estimated to diminish productivity by $2.9 billion each year1.  
 
In recognition of the public health impact of trachoma, the WHO established the Global 
Alliance to Eliminate blinding Trachoma by 2020 (GET 2020). A multi-faceted strategy to control 
all phases of trachoma has been endorsed by the WHO. It consists of Surgery (to repair lids 
distorted by trachoma (trichiasis) in imminent danger of vision loss), Antibiotics (mass antibiotic 
treatment to reduce the community pool of infection with Chlamydia trachomatis), Face washing (to 
reduce transmission from ocular and nasal secretions), and Environmental improvements (to 
interrupt transmission and prevent re-emergence). With even partial implementation of the SAFE 
strategy to 80% of those who need it, it is estimated that over 15 million DALYs per year globally 
would be saved2.  
 
However, the trajectory for elimination of trachoma in these countries has been 
disappointingly slow. How long and with what frequency must we mass treat communities with 
antibiotics for active trachoma to achieve elimination? While WHO has recommended mass 
antibiotic treatment coverage targets of 80%, there are no solid data on how high the coverage 
should be and the frequency of administration. High antibiotic treatment coverage rates, and 
                                                                        
1 Frick KD, Basilion EV, Hanson CL, Colchero MA Estimating the burden and economic impact of 
trachomatous visual loss. Ophthalmic Epidemiol. 2003 (2):121-32 
2 Baltussen RM, Sylla M, Frick KD, Mariotti SP Cost-effectiveness of trachoma control in seven 
world regions. Ophthalmic Epidemiol. 2005;:91-101 
Chapter 
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repeated treatments, may eliminate infection in some communities, but with almost a three to five 
year lag time between reduction in infection and significant reduction in the clinical signs of 
trachoma, communities remain targets of resources for mass treatment even when such resources 
may be better-deployed elsewhere3. Even with high coverage, some treated children with high loads 
of infection continue to have infection post treatment, arguing for approaches to targeted 
surveillance or more frequent coverage4. With renewed interest in trachoma as a “neglected tropical 
disease”, and the possibility where ecologically justified of integrated programs, there is an even 
more urgent need to clarify how best to use azithromycin.   
 
The consortium brings together the leading trachoma research teams, at Johns Hopkins 
University (JHU), the London School of Hygiene and Tropical Medicine (LSHTM), and the 
University of California at San Francisco (UCSF). Consortium partners include Pfizer, who have 
pledged antibiotics for this project, advocacy partners including WHO and the Trachoma Control 
Programs in Tanzania, Niger, and The Gambia.  
 
2.2 Anticipated Impact 
 
Working with Ministries of Health and Niger’s country programs, this trial of mass antibiotic 
intervention has the potential to alter the trajectory of blinding trachoma dramatically. This includes 
areas of hyperendemicity where programs have not yet started on a large scale as they have in other 
parts of the country.  No other research partnership has the breadth and ability to undertake such a 
comprehensive, and critical, proposal for trachoma control. We have proposed the dissemination of 
results in a format for country National Trachoma Control programs and Ministry of Health, the 
ultimate end users who need this evidence base to drive improvements in implementation of SAFE 
for trachoma elimination.      
 
 
 
 
                                                                        
3 Solomon AW, Holland MJ, Alexander ND, Massae PA, Aguirre A, Natividad-Sancho A, Molina S, 
Safari S, Shao JF, Courtright P, Peeling RW, West SK, Bailey RL, Foster A, Mabey DC.Mass 
treatment with single-dose azithromycin for trachoma.N Engl J Med. 2004;351:1962-71 
4 West SK, Munoz B, Mkocha H, Holland MJ, Solomon AW, Foster A, Bailey RL, Mabey DCW. 
Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in 
Tanzania: a longitudinal study. Lancet 2005;366:1296-1300 
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Chapter 3: Randomization Arms and Sample Size 
________________________________________________________________ 
 
3.1 Overview: 
 
We propose to randomize communities in a 2 X 2 factorial design within Niger.  
Communities will be randomized (12 in each arm) to two different coverage targets (80%-89% 
versus ≥90%) for three years of mass treatment. Communities will be further randomized to annual 
mass azithromycin distribution for everyone versus every 6 month distribution in children ages 
twelve and under.  
Sentinel children age five years and younger will be randomly selected from each community 
based on census of the community, as cross sectional samples of the rates of trachoma and 
infection. The census will be updated each year, and villages monitored at baseline, 6, 12, 18, 24, 30, 
and 36 months for infection and clinical disease. The three-year study is in accord with the WHO 
guidelines for three years of annual mass treatment followed by a re-survey to determine need for 
further treatment. 
 
3.2 Randomization Arms 
 
The basic structure of the trial is shown in the table below.  In this 2 X 2 factorial design, 
communities will be randomized into four treatment arms. All communities will receive mass 
treatment with azithromycin at baseline. At present, recommended coverage of the community is 
80% or better. We propose to evaluate the effect of two coverage targets, (estimated in children age 
0 to 9 years old). The two arms would have 1:1 randomization at community level to one of two 
coverage targets:  80% to 89% coverage (reasonable program targets) and ≥90% (enhanced program 
coverage, requiring additional time and resources). Niger will be participating in the randomization 
arms for coverage, in order to determine the incremental effectiveness of extra effort in coverage in 
reducing infection and disease.  
 80-90% Antibiotic 
coverage target 
>90% Antibiotic 
coverage target 
Annual azithromycin  
to everyone 
Arm A Arm B 
Biannual azithromycin 
to children 
Arm C Arm D 
 
 
The second component of the antibiotic trial is frequency of administration of mass 
treatment.  We propose two frequencies of mass antibiotic administration, yearly for everyone in the 
community and every six months for children ages twelve and under.   
Chapter 
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3.3 Communities and Sentinel Children 
 
In order to determine the impact of our treatment arms on trachoma and infection, we will 
randomly sample a sentinel group of up to 100 children within randomly selected communities. We 
define communities as the smallest population unit for which health services are organized and trachoma control 
programs are implemented.  In Niger we will use villages comprised of 250-600 people.  As described 
below, we plan to have 12 communities in each cell of the Niger arms. We need multiple 
communities to have a stable estimate of the impact of the treatment arm.  
 
In Niger, 48 grappes (villages) of population size 250-600 people and approximately 50-100 
children in the eligible age range cover the district of interest.  
 
For this trial, we propose to monitor the changes in prevalence and infection over time 
according to treatment arm. For this, simple cross sectional samples of 50-100 children ages 0 to 5 
years within the community at specified times are sufficient. This sample will enable us to determine 
the effect of treatment after each round.  This sample will not be followed longitudinally, and at 
each sampling time, a new random sample will be drawn. To support the sampling, a census update 
will be performed yearly.  
 
3.4  Sample Size   
 
 3.4.1 Villages   
 
We estimated the sample size requirements for our two-by-two factorial design using 
simulation. Briefly, we generated simulated data assuming the alternative hypothesis and determined 
the sample size needed for how often (selecting 80%, our desired power) our statistical test would 
yield a rejection of the null hypothesis. We adopt a non-inferiority design5 for each factor with non-
inferiority limits of 8%. Assuming a standard deviation of 0.05 within each arm, a correlation of 0.5 
between baseline and 36 month results (derived from previous studies), and no interaction between 
factors, we estimate that a total of 32 communities provides greater than  80% power for each main 
effect (95% one-sided non-inferiority).  Smaller community sizes imply a higher variance.  
Conservatively, we assumed the variance was one third higher.  Thus, to obtain greater than 80% 
power, we require 12 villages in each arm (for a total of 48 villages, again assuming a one-sided 95% 
non-inferiority comparison with limit 0.08).   
 
We show the sample size for each hypothesis and assumption, recognizing the simple 
approach requested is not the analytic plan, and show that the simulation approach yields 
comparable estimates, and which includes consideration for our approach to analyses.  
 
1) What are differences at 3 years post baseline in rates of trachoma and ocular Chlamydia 
trachomatis in communities randomized to mass antibiotic coverage of low (80-89%) versus 
high (>90%) coverage. 
 
                                                                        
5 Chow SC, Liu JP. Design and Analysis of Clinical Trials, 2d ed. New York, John Wiley, 2004 
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We hypothesize that higher coverage (as measured in ages <10 years) will result in lower prevalence of infection at 
three years in Niger. 
 
In principle, this could be addressed by a two-sample T-test. We estimate that the inclusion 
of 12 communities per arm in Niger will provide greater than 80% power to detect a 6% difference 
in the prevalence of infection in individuals 0 to 5 years of age at 36 months, assuming a standard 
deviation of 5.0% and a two-tailed alpha of 0.05.   
We have used our judgment to propose that a 6% difference in the prevalence of infection is 
the clinically relevant difference we wish to detect. After three years of mass treatment, we expect 
infection rates to be low, and the difference in terms of re-emergence between, for example, 2% and 
7% is insignificant. Similarly, re-emergence rates may be higher, but we do not expect differences in 
the rates, if at three years infection rates are 10% to 15%.   
 
2) What are the differences at 3 years post baseline in the rate of ocular C.trachomatis in 
communities randomized to mass antibiotic treatment of children every 6 months versus 
yearly treatment of everyone?  
 
We hypothesize that treatment of children every six months will result in a lower prevalence of trachoma, infection at 
three years in Niger compared to yearly treatment of all residents. 
 
As with Hypothesis 1, this could be addressed by a two-sample T-test.  We estimate that the 
inclusion of 12 communities per arm in Niger will provide greater than 80% power to detect a 6% 
difference in the prevalence of infection in individuals 0 to 5 years of age at 36 months, assuming a 
standard deviation of 5.0% and a two-tailed alpha of 0.05.  This computation was conducted using 
the same computation as for Hypothesis 1. 
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Chapter 4: Eligibility, Consent and Enrollment 
  
4.1 Eligible Communities 
 
This study aims to determine the impact of different approaches to mass treatment on 
prevalence of trachoma and infection in villages that are hyperendemic for trachoma. Eligible 
communities are described below: 
   
To be eligible for the trial in Niger, a community must meet the following criteria: 
 
1. The community must be located in the target district around Matameye 
2. The village chief consents to participation in the trial (this does not obviate the need for 
individual consent, but without overall leadership consent, the community as a whole cannot 
be part of the trial)  
3. Communities must be more than four kilometers away from the center of any semi-urban 
areas, which are thought to have a lower prevalence of trachoma  
4. Communities must have an estimated population of between 250-600 people. 
 
4.2 Eligible Children 
 
Within each community, we will monitor the following children in all 48 grappes: 
 
1. The child is age 5 years and younger 
2. The child must be a resident in an eligible, sample community (defined as either living in the 
community since birth, or moved in with parents or guardians).   
3. The child must not have an ocular condition that would preclude grading trachoma or taking 
an ocular specimen. 
4. The child must have an identifiable guardian capable of providing consent to participate. 
  
Note that in 2 grappes of each of the 4 arms, we will monitor all 0-9 year-old children. 
 
4.3 Consent Procedures 
       
Several levels of recruitment are involved when working in Niger.  At the community level 
our research team discusses the project with local leaders.  This information is then imparted 
throughout the community where the research project and participation is discussed.  Study 
personnel will address specific questions the community may have before allowing us entry.  
 
Chapter 
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Once leadership consents to participation, we will undertake a complete census of study 
areas by going house to house in each community. At this second level, we ask permission of the 
head of the household or an adult dwelling in the household to collect data on household 
characteristics and the age and gender of each resident of the household. At this time, we explain the 
following: the census will be used to monitor the uptake of mass treatment in the community and to 
draw a random sample of children ages 0-5.  These children may be eligible to be in the surveys that 
will be done at baseline, and every six months after mass treatment. At this point we describe what 
the survey entails (trachoma assessment of the child, and a swab taken of the upper eye lid to detect 
chlamydia, the bug that causes trachoma). We ask them to consider that, if the household contains a 
child of eligible age who is selected, we will return to seek permission to examine the child.  
 
Local team members will provide information and seek consent.  The study coordinator will 
train the team in research ethics and informed consent.  The team will explain that the purpose of 
the project is to determine severity of trachoma and infection before and after treatment by 
examining a sample of the children in the village. They will demonstrate the use of the swab and 
explain that participation is completely voluntary and will not affect access to health care or access 
to the mass treatment to come after the survey.  Additionally, they will explain that different villages 
will receive different treatments in an effort to determine the best treatment, and that treatment for 
trachoma will be provided to everyone in the village once examinations are completed. 
    
4.4 Risks and Efforts to Minimize Risk 
    
There are minimal risks to the participants. Flipping the eyelid is only slightly uncomfortable 
and most children are not bothered by the procedure (in fact, many children can do it themselves). 
The swab is uncomfortable, and can be a painful procedure if the eye is very inflamed. However, the 
procedure does not harm the child, other than upset them for a few moments if it is uncomfortable. 
By informing the parents about the clinical status of the child, and motivating them to seek 
treatment, the assessment is actually helpful. There is no alternative to the clinical examination for 
determining trachoma status. 
 
Procedures for protection against risk include the following: we are careful to have a single 
individual flip the lid while the senior lab technician carries out the   examination, takes the swab, 
and the photograph of the upper eye lid. In this way, any psychological trauma to the child, or 
discomfort from having the eyelid flipped is minimized as the lab technician can work quickly. In 
addition, by having the person hold the eyelid, the swab procedure can be done safely without worry 
of accidental corneal scratch. We have never had an accident in all the years we have taken swabs for 
trachoma using these procedures. In the unlikely event of a corneal scratch, the team has an eye 
patch and topical tetracycline and can treat the scratch immediately.  The results of the examination 
are told to the parents immediately after the examination, and not revealed to other members of the 
village.  
 
The forms are stored in a folder, which after data entry, is kept in a locked file room. The 
data are transmitted to the main data centers without names, just identification numbers. Such 
procedures ensure confidentiality.     
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Chapter 5: Procedures: Census of communities 
____________________________________________________________________ 
 
5.1 Overview 
 
The census is a critical piece of data collection, as it is the document by which we measure 
coverage of mass treatment in the community, and it is the sampling frame for drawing a random 
sample of children in each community. Once the communities have been selected, and agree to 
participate, the survey teams will then conduct a full census.  
  
In the context of this trial, as described earlier, the community is a village (population of 
250-500 people).      
 
5.2 Baseline Census 
 
The census team will meet with the community leaders, and collect a list of the head of 
household names.  
 
Each of the community leaders will assign a knowledgeable community resident to escort the 
census team member to the households under his/her jurisdiction. The household will be assigned a 
unique identification number which will be affixed to the door. These numbers will correspond to a 
community number followed by a unique three digit ID for that household.  At the end of the 
census, the census team leader will go through the community to be sure that there is no door that is 
missing a number. If a household prefers not to have a permanent number affixed to the door, they 
will be asked to at least have a plastic sheet with the number taped to the door for the duration of 
the census so that they are not visited and enumerated more than once.  
 
For each household, the census team member will ask to speak with either the male or 
female head of household to obtain a list of the names of all persons resident in the household, ages 
and gender.  The definition of resident in the household means a person who has slept in this 
household for at least three month in the past or who intends to reside with the family for the next 
six months. The age of the children needs to be as precise as possible, as they comprise our sample. 
Event calendars specific to each location will be used to tie ages to such events as elections, weather 
events, significant deaths, etc.  
 
Other demographic information to be collected in all sites will include education completed 
by the head of the household, distance to the closest source of water, and observations on clean face 
status of children, presence of latrines, and cleanliness of the area around the doorway of the 
household. These measures enable us to further characterize households in communities where 
Chapter 
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sustainable reduction in disease and infection has occurred, and enable us to measure any 
environmental effect on reduction in infection.   
 
The census data are entered into the data base using customized data entry forms in access 
that are standard across all clinical sites.  
 
5.3 Interim Census   
 
The census will be updated at each year for the following three years. The procedures are 
exactly the same for new households that come into the village since the previous census. The same 
census information will be collected on the household and each person in the household. For new 
additions to the households, or loss of persons in a household, addendums to the census list will be 
made indicating the age, gender, and relationship to head of household for the additions, or reasons 
for deletion of a person (death or permanently moved to another community). If the person has 
simply moved within the village, they will be deleted from their previous household and added to 
the new household using the update census form.  
 
These updated census lists will be used to draw a new random sample of children at each 
yearly survey, and provide the denominator for the mass treatment interventions.  
 
Census data will also be updated during the time of the surveys. If children have died or 
moved, or households have moved away, then census update forms will be generated at the time of 
the survey to update the census list. The data from the surveys will only be able to update the status 
of children who were randomly selected for survey, but we will capture that information.   
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Chapter 6: Procedures: Study Visits 
_______________________________________________________________ 
 
6.1 Overview 
 
The purpose of the study visits is to collect the basic data on the sentinel children who will 
represent the community burden of trachoma and ocular C. trachomatis infection over time. Once the 
sentinel children are selected in each community, the study team will examine them for trachoma 
and take swabs for determination of laboratory evidence of infection. Swabs are sent to the 
laboratories for processing. New cross-sectional samples will be drawn at each study visit, using the 
latest census survey as the sampling frame, and following the random selection procedures. The 
sample of 100 children can be examined in a single day, so we have set aside one day for the 
examinations and a second day for any wrap up. For logistical reasons, the teams cannot make more 
than two visits to a single community, so children who are not available for the examination within 
two days will be replaced from the alternate list.       
       
After the baseline visit, the villages receive mass treatment according to randomization 
schedule with follow-up visits and further mass treatments scheduled thereafter for three years. In 
the next sections we describe the content and procedures for the baseline and follow-up visits.  
  
The study team for these visits consists of an intake clerk, a trachoma 
grader/photographer/lab technician, and a driver. There maybe separate persons who perform the 
functions of trachoma grader, photographer, and lab technician, and person who may perform 
tubing. A person whose job it is to solely flip lids may also be part of the team, and can help the 
others be more efficient. Because these functions may be combined in different ways, we describe 
the job, rather than the person.       
 
6.2 Baseline Visit 
  
Once the child is selected, the family is notified of the selection. In some cases the child is 
examined in his or her home, and in other cases the family is asked to bring the child to a central 
location in the neighborhood.  
  
The child arrives for the examination and is checked in by the intake clerk. The intake clerk 
has a Master List of eligible children for the community and a stack of pre-printed ocular 
examination forms with the child’s study identification information on the form. The intake clerk 
checks off the child as arriving on the Master List. The intake clerk completes the informed consent 
procedures. If the guardian agrees to have the child be part of the survey, then the intake clerk signs 
Chapter 
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the witness for verbal consent form. The intake clerk hands the guardian the correct ocular form 
with the attached labels, and instructs the guardian and child to wait for the examination.  
  
The intake clerk keeps count of the children who are examined, and notes those who have 
failed to show up for an appointment. S/he assigns the community health worker to go to the 
households of children who have not appeared and determine the reason. We will make every effort 
to include such children, including offering transportation to and from the exam site, or a home 
visit. If the child has moved permanently or died, then the intake clerk will select a household and 
child from the alternate list, and complete a census update form.  If the child is not available during 
the examination times in the community due to travel or illness, the reason is noted on the Master 
list, and again an alternate child is selected.  
  
At the end of the day, the intake clerk must account for all children on the Master list of 
eligible children. Either they have presented for examination, or a reason is provided for non-
attendance, and an alternative appointment scheduled or an alternate selected.  If the list is 
incomplete, the survey team must wait until the households are visited and the child is examined, 
another appointment made, or an alternate is examined.          
 
The following describes the details of the procedures for the examination. An ocular exam 
form is completed as a record of the examination.  
  
6.2.1  Trachoma Assessment 
 
Equipment needed: ocular exam form, black pen, torch light, 2.5X loupes.  
 
 Before examining the child, the grader should examine the ocular form, be certain it contains 
labels for the swab and check if a photograph is necessary. The examiner should call out the child’s 
name and ascertain that the child (by name age and gender) is correct. If incorrect, the child and 
guardian should be sent back to the intake clerk for resolution-either the form sent in was incorrect, 
or the wrong child was brought for the examination.  
 
 To examine the patient for trachoma, it may be necessary to have guardian hold the child 
securely in the lap, with the child’s legs around the guardian’s waist and the guardian holding the 
child’s hands. The child’s head is then in the lap of the examiner/lid flipper. The child is told to look 
“down” at the guardian, as it is easier to flip lids. Once the person who flips the lids has on a new 
pair of gloves, s/he should NOT touch the child anywhere else but on the eyelid to ensure no 
contamination. Trachoma is assessed by flipping the upper eye lid and examining the tarsal plate for 
evidence of trachoma. Be certain that the pressure on the upper eye lid as it is everted is not too 
strong or it will blanche and make grading very difficult. If necessary, let go of the lid between 
grading and photography. The left eye is flipped first, and graded, followed by the right eye; the right 
eye is then photographed (if selected) and swabbed. The person who flips the lids will be wearing a 
pair of gloves which are changed before each new patient. The trachoma grader or lab technician 
may or may not be the “lid flipper”.    
  
We will use the WHO simplified grading scheme for trachoma, which assesses the presence 
or absence of follicular trachoma (TF), intense trachoma (TI), conjunctival scarring (TS), trichiasis 
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(TT), and corneal opacity (CO).6 For this study, the relevant signs are TF and TI, signs of active 
trachoma. TF is defined as five or more follicles in the region of interest of size 0.5 mm. If there are 
fewer follicles, then TF is graded as not present. TI is defined as inflammation severe enough to 
obscure 50% of the deep tarsal vessels. Occasionally, but rarely in children, there is scarring 
sufficient to obscure the vessels-however, this is not TI as the obscuration is not the result of 
inflammation. Where scarring is this bad, the eyelid may be labeled as “cannot grade” for signs of 
active trachoma.  The data on the presence or absence of trachoma signs is entered onto the form.  
  
If more than one grader is used, graders will be assigned randomly to intervention and 
control communities, to ensure no subtle grader bias due to doing only one kind of village exists in 
the treatment arms.   
  
6.2.2  Laboratory Procedures  
 
6 . 2 . 2 . 1  SPEC IME N C OL LEC TIO N  
Equipment needed: sterile swabs, swab vials, labels, ocular swab shipping list. 
 
Each sentinel child must have an ocular swab taken for determination of infection. If the 
child refuses the swab, or a swab cannot be taken for another reason, then the child is ineligible. The 
intake clerk should be notified that the child is ineligible, a note made in ink on the ocular 
examination form and in the Master List of Eligible Children, and an alternate household and child 
selected as replacement.   
 
Each ocular form has a set of printed labels with the child’s study identification number. 
One label is placed on the ocular form in the section asking if a specimen was taken, one on the 
study vial after the swab is inserted, and one on the shipping log for the box in which the vial is 
inserted. In this way, each vial box has an accounting of specimens for subsequent shipping. There 
are extra labels as well, if one is lost or torn.  
 
We will be taking a field control swab for each laboratory technician sufficient to have 50 
control swabs per survey. These will be taken using the “blue air” swabs that will be pre-marked in 
each box of swabs.      
 
6 .2 . 2 . 2  PR O TOC O L F OR SWA BBIN G  O F  TH E C ON J UNC TIVA  
1. Upon taking a swab from the box, the lab technician will announce what type of swab 
it is: 
 An unmarked “plain swab”, indicating no control collection necessary for this 
patient. 
 A "blue air swab" (negative field control), indicating examiner must collect a 
second swab for this patient.  Swab sachet will be marked with blue color.   
2. The swab sachet should be opened in a sterile manner, revealing only the tip of the 
swab shaft, with the swab head itself remaining sterile deep within the sachet. 
 
3. If the child needs an ocular photograph, this must be taken prior to the swab. When 
ready to swab, the lab technician should slowly pull out the swab (if removed too 
quickly the Dacron swab tip can unravel).  The gloved hand should be held no closer 
                                                                        
6 Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its 
complications. Bull World Health Organ. 1987;65(4):477-83. 
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than 1 inch from the Dacron polyester swab tip during the entire swabbing procedure, 
in order to avoid contamination of the swab tip. 
 
4. As the lid flipper (who may be the technician) holds the right eyelid in the everted 
position, the technician swabs the upper tarsal conjunctiva of the child with a gloved 
hand, using a steady and firm swab.  The swab should be placed flat, with its entire 
length parallel to the conjunctiva to give the greatest surface area of contact, and if 
necessary, this may require repositioning of the child’s head by the examiner.  The 
swab should be drawn firmly in one direction over the conjunctiva with enough 
pressure to cause blanching of the conjunctival vessels.  The swab should then be 
rotated 120 degrees along its axis and the newly revealed fresh region of Dacron on 
the swab tip should now be drawn firmly across the conjunctiva.  The swab should be 
rotated another 120 degrees along its axis and the conjunctiva swabbed for a third 
time.  This will ensure sufficient collection of conjunctival epithelial specimen for PCR 
analysis in the lab. 
 
6 . 2 . 2 . 3  PCR C O N TR OL  SW A BS  
A negative field control ("blue air swab") will be taken on a randomly chosen 5 children per 
village to assess the frequency of contamination.  For each negative field control, the examiner will 
pass a sterile Dacron swab within 1 inch of the child’s conjunctiva. Control swabs are taken after the 
original swab but before changing gloves for the next participant. A label from the control set, made 
to look like a regular ID but indicating a control swab will be used. One label is affixed to the ocular 
form in the indicated area and one is affixed to the vial.   
  
6 .2 . 2 . 4  PR O TOC O L F OR TU BIN G AND  HAN D L IN G O F S AM P LE S  
 The tubing and handling protocol must be carefully followed in order to prevent 
contamination and ensure the safe transport of the samples to the microbiology laboratory.  The 
person in charge of labeling, tubing, arranging, and handling the samples needs to perform this task 
in the most orderly and attentive manner. 
 
1.  The tuber should wear gloves on both hands at all times.  The tuber's gloves only need to 
be changed when any potential contamination of the gloves occurs. The tuber opens the 
capped, hinged lid of a microcentrifuge tube, which has been labeled with the participant’s 
random identification number. If it is a control or “blue air” swab, then the label comes 
from the control set of labels.   
 
2.  The swab is inserted by the lab technician (using the still-gloved hand that swabbed the 
participant’s conjunctiva) into the microcentrifuge tube held by the tuber.  The swab shaft 
should only be inserted until the Dacron swab head is fully in the tube.  The tuber should 
lower the cap onto the swab shaft held by the examiner, and the examiner should quickly 
break the swab shaft using a swift downward snapping wrist movement. 
 
3.  The tuber will screw the cap of the microcentrifuge tube tightly and place it in the sample 
collection box, located in the cooler bag filled with frozen ice packs. The flap of the cooler 
bag should be closed between each patient.  The cooler bag should be in as cool a place as 
possible in the field, in a shaded area out of the sun. 
 
4.  Upon returning from the field each day, the samples will be immediately taken to the 
health center and stored in a freezer, reserved solely for storage of specimens and ice packs.  
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All samples will be in sample boxes, labeled with the village and district names for easy 
future identification. 
  
6.2.3 Shipping and Storage of Samples 
In accordance with the Roche COBAS AMPLICOR™ CT/NG protocol, swab samples 
taken in the field will be transported on ice in a closed, insulated container until arrival at the Proctor 
Foundation Microbiology laboratory in San Francisco.  Samples will be imported to the USA per the 
CDC Permit to Import/Transfer Etiological Agents or Vectors of Human Disease. 
 
1. Materials for shipping to the US 
 Insulated shipper box (ThermoSafe VIP insulated shipper, 615DCS or 499 DCS) 
 Gel Packs (ThermoSafe U-tek 24 oz. -10°F) 
 Shipper label 
 Consignee label 
 Responsible person label 
 UN3373 label 
 Biological substance, Category B label 
 Documentation to include in shipper box 
o Pro-forma invoice  
o Letter from Shipper 
o CDC permit 
o Letter of approval from Ethics committee in country  
o airway bill from ;world Courier, DHL, or other air transport service 
 
2.  Packing the samples 
 
For dry samples without media:  
 Boxes can be wrapped with plastic wrap and clear plastic tape.   
 Boxes may also be wrapped with a cotton absorbent pad (chuck) for improved 
insulation. 
 As soon as samples are prepared for shipping, they should be returned to the -20°C 
freezer to prevent samples from thawing.   
 Place all stickers on outside of the shipper box (see detailed shipper instructions). 
 Leave at least one shipping box, preferably a partially-filled one, unpacked for 
inspection by the air shipper employee and or customs.  
 
When ready to ship, the prepared sample boxes should be placed into the partially filled 
shipper box.     
 
Next, all frozen icepacks and samples should be placed in the shipper box.  (6 gel packs for a 
small shipper, 12 gel packs for a large shipper)    
 
 For a small shipper box:  Use 6 frozen gel packs-- one below sample boxes, 4 on 
each side, and one on top of sample boxes 
 For a large shipper box:   Use 12 frozen gel packs-- 6 gel packs flat at the bottom and 
6 on the top 
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Immediately after the shipment is accepted by the shipping company, the shipper box 
should be closed and taped shut using clear plastic tape. Tape should be placed around all corners of 
the outside box.   
 
6.2.4 Laboratory Processing Procedures  
A dry swab is taken in the field, a study identification label is affixed, and the vial is kept 
frozen until it reaches each country team’s designated laboratory as described above.  The specimens 
are processed according to strict protocol, outlined in the manufacturer’s kit directions, followed by 
the Microbiology Laboratory at the Proctor Foundation.  We will use the Roche Amplicor C. 
trachomatis qualitative PCR assay from Roche Molecular Systems. Procedures are summarized as 
follows: Each swab is eluted by vortexing in Amplicor CT/NG lysis buffer in polypropylene tubes, 
then Amplicor specimen diluent is added. Using a known positive sample in the laboratory, we will 
create positive and negative C. trachomatis (CT) processing controls; two CT+ and two CT- 
processing controls are run with each batch of specimens. The Working master mix is created and 
the specimens prepared prior to amplification. The specimens and controls are placed in the thermal 
cycler for amplification. Once completed, the specimens are denatured, and sent for detection using 
probe-coated microwell plates. Detection is accomplished by measuring the optical density at A450 . 
The assay result for the negative controls should be less than 0.2 A450, and the assay result for the 
positive controls should be 0.8 or greater for ocular specimens for a valid run. We will test separately 
for amplification of both the target plasmid DNA and the master-mix internal control samples to 
determine if PCR was inhibited. Samples whose values in valid runs are 0.8 A450 are counted as 
positive, and samples less than 0.2 A450 are negative. Samples for which the result are equivocal 
(0,2, <0.8) will be tested again; if equivocal twice, they are left as equivocal and called not positive 
in the analyses as no run equaled 0.8 or greater.     
 
6.2.5 Photograph Grading   
Equipment needed: camera, memory card, labels, fully charged battery, photolog book, CD 
burner 
Optional: extra battery, memory card reader  
 
 
An ocular photograph will be taken of the right eye of every nth child sufficient to ensure at 
least 50 photographs per trachoma grader per visit.  
 
Clinical photography will be performed before conjunctival swabbing.  A handheld Nikon 
D-series camera with a 105mm f/2.8D AF Macro Nikkor Autofocus Lens (fully extended, in manual 
setting) will be used. If possible, use natural light to help position the patient but all photos are taken 
with falsh engaged. Camera set-up is as follows: 
 
 Image settting .jpq, fine, large 
 White balance A or Flash 
 Flash from camera body snapped up into position. 
 Aperture-preferred, set at F32 or higher  
 ISO 320- this can be increased if needed to maintain high F-stop 
 
Several photos will be taken: first, a photo will be taken of the patient identification number 
(which can probably be done with or without flash).  The image is brought into focus by coming to 
the appropriate distance from the conjunctiva.  Note that the camera itself is not focused—the 
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macro lens should always remain in the fully extended, 1:1, manual setting.  A sharp image is 
obtained by positioning the camera and lens, not by changing the focus of the lens. At least two 
photos will be taken of the right upper conjunctiva.  The patient is placed into the examination 
position, either sitting, standing, or in the “head-clamp” position.  The photographer focuses on the 
blood vessels of the upper lid, getting them (if visible) into sharp focus. If the eyelid is blanched 
from being everted, pressure from the everting finger can be reduced. Two photographs of the 
eyelid are taken. 
 
Photos are immediately reviewed for grade-ability and re-taken if necessary.  All of the 
following are considered unacceptable photos (with possible solutions in parentheses): 
 
1) out of focus (OK to increase F-stop higher than F-32 to increase depth of field). 
2) too much water on the conjunctiva (can gently dab with swab—don’t rotate or move swab 
across conjunctiva, as this can create inflammation) 
3) not centered (hold child more firmly, photographer can rest arm to steady) 
4) conjunctiva not fully exposed (OK to use more than one finger, hand, or swab for better 
exposure). 
5) Conjunctiva blanched from too much pressure everting (reduce pressure, allowing blood 
flow back into conjunctiva. 
 
 If the child cannot be photographed for some reason, it does not affect the eligibility of the 
child. A notation is made on the ocular form of why the photograph cannot be taken, but no 
replacement is sought.  Again, this is expected to be a rare event. 
 
 Images are stored in digital file folders according to study ID number. They are burned onto 
a CD every week and sent to LSHTM where they are graded for quality assurance purposes by Dr 
Robin Bailey, who is the standard grader for the PRET study.  
 
6.2.6 Follow-up of Children 
 All children on the Master List of Eligible children for each community will be followed up 
with if they are not initially available for examination. If necessary, families will be offered free 
transportation to the examination site and back, or a home visit in order to assist in overcoming 
barriers to the examination. If the child/household is temporarily away, another appointment will be 
set up for a second day. If the child is too ill to be examined, refuses, has died, the household has 
moved permanently, or travel exceeds the time the study team can be in the community, then the 
next household and child from the alternate list will be selected to participate. When the alternate 
child is selected, the Master list will be updated to indicate which child is being replaced, and the 
Study Identification number of the replacement child if additional data on the child or household is 
found that necessitates a change to the census list, then an update census form will be completed.  
  
For the longitudinal study villages where all children under age 10 years are enrolled, efforts 
will be made to include all children as there are no “replacements.”        
 
6.3 Forms and Swab Management for Visits 
 At the end of the examination day, when all children on the Master List of eligible children 
and the alternates have been accounted for, three reconciliations will take place. First, the lab 
technician will be certain that each tube has a label. If one is missing, the forms and tubes should be 
matched to determine which label is missing. If more than one tube is missing a label, then the 
children may need to be re-swabbed to be certain the trachoma grade corresponds to the correct 
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laboratory determination of infection. The number of tubes must also match the number of ocular 
examination forms. If there is a mismatch, then the tubes and forms should be matched to 
determine what is missing. If an ocular examination form was missing or not filled in, the child must 
be re-examined. Similarly, if a tube is missing, and there is no notation that a specimen was not taken 
for a reason, then the child must be re-swabbed. Once the swabs and ocular forms are reconciled, 
the ocular forms are given to the photographer.  
 
The photographer reviews his/her photolog to be certain that where a child was to have 
digital images of the eyelid that the photograph was taken or a notation made as to why the 
photograph was not taken.  
 
The intake clerk will compare the ocular exams in hand to the Master List of eligible children 
to be certain that each child who presented was examined. If an ocular form is missing but the child 
is listed as having presented, then the study team must return to the household and reconcile the 
difference, likely by re-examining the child.  
 
The intake clerk must account for each child on the Master List of Eligible children for the 
community, either with an ocular form, a notation on the list (in which case there is an alternate 
child chosen); also if the notation states the child has died or permanently moved out of the 
community, or moved within households, then a census update form should also be present.       
 
6.4 Missed Visits 
 Missed visits, for the purpose of this trial, occur if a community cannot be seen within the 
window of plus or minus two months. The four month window keeps the village visit largely during 
the same season as the original scheduled visit.  
 
6.5 Follow-Up Visits  
 The first mass treatment is carried out immediately after the baseline survey. Subsequent 
follow-up visits are at 6, 12, 18, 24, 30, and 36 months from the first mass treatment. The census 
lists are updated formally every year prior to the 12, 24, or 36 month survey. The 6, 18, and 30 
month surveys will use the census lists for the previous survey when drawing new random samples 
of sentinel children. The window for each survey is +/- two months.  
 
The exact same procedures as stated for the baseline examination visit are to be followed for 
all subsequent examination visits. In all cases, mass treatment according to treatment arm is to 
follow immediately after the survey, to ensure that children are not treated prior to the survey.  
  
6.6 Study Visit Sample Schedule 
 As noted earlier, we have two days in each community to schedule examinations.  
Depending on the starting month, we have flexibility in the schedule to work around holidays and 
rainy seasons.  If the rains are heavy, we will alter the schedule of surveys, and allow a window of 
+/- two months for the community examinations.  
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Chapter 7: Intervention: Mass Treatment Implementation  
_____________________________________________________________________ 
 
7.1 Overview: Treatment with Azithromycin  
 
 The intervention for this trial is community treatment with azithromycin, a single dose 
antibiotic highly effective against Chlamydia trachomatis. Antibiotic sufficient for this trial has been 
donated by Pfizer international to the National Trachoma Control program in Niger. The dosage is 
20mg/kg, up to 1 gm in a single dose of either liquid (for children) or tablets (for children able to 
swallow tablets and adults). Children below 6 months of age are not treated with azithromycin but 
are given topical tetracycline for trachoma.  
  
Azithromycin has been extensively studied for mass use in trachoma control, and has been 
found to be very effective and well–tolerated. In the ACT trial, no significant adverse effects in 
children and adults were noted in Tanzania, Egypt, and The Gambia7. In the STAR trial, which 
treated adults, no differences in adverse events were noted between topical tetracycline and oral 
azithromycin8. Initial potential concerns for creating clinically significant resistance in other 
organisms to azithromycin do not appear to be realized9. On the basis of these and other studies, 
Niger has undertaken mass drug administration for their communities, with education to residents 
that any GI concerns be directed to local health centers and posts for treatment. We anticipate using 
the same local network to monitor any self reported adverse events.  
 
7.2 Six monthly Mass Treatment  
 
Models imply that children form a core group for the transmission of trachoma—if infection 
can be eliminated in this age-group then it would presumably fade away in adults, whose treatment 
now requires a substantial portion of a program’s resources.  We have demonstrated that treating 
children alone can be successful in an area with a modest amount of trachoma.  A recent study in a 
                                                                        
7 Schachter J, West SK, mabey D, et al. Azithromycin for Trachoma Control. Lancet 1999;354:630-5 
8 West SK, West ES, Alemayehu W, Melese M, Munoz B, Imeru A, Worku A, Gaydos C, Meinert 
CL, Quinn T. Single-dose Azithromycin prevents trichiasis 
9 Gaynor B, Holbrook KA, Witcher JP, et al. Community Treatment with Azithromycin for 
trachoma is not associated with antibiotic resistant S. Pneumoniae at One year.  Br J Ophth. 
2003;87:147-8 
Chapter 
7 
P R E T  M A N U A L  O F  O P E R A T I O N S  
PRET MOO Version 6 – 20Noveber2008                                                                                  26 
 
hyperendemic area of Ethiopia also demonstrates a degree of community protection in older, 
untreated individuals after quarterly treatment of children only.  
 
Therefore, in addition to evaluating two coverage targets for the entire community, we will 
be evaluating whether biannual treatment of children is as effective as annual treatment of all 
individuals in a community.  12 villages will be randomly assigned to a coverage level of 80%, and 12 
to 90%, with children ages 0-12 (i.e. newborns to those less than 13) receiving treatment every 6 
months.    
 
Bi-annual treatment visits will be organized and implemented in the same way as annual 
treatment visits, except that only children 0-12 will be treated in these communities (12 villages 
assigned to standard coverage and 12 assigned to enhanced coverage).  Any questions regarding this 
exclusion category by community members will be clearly addressed and explained by local health 
workers, who will have received training in this area.  All children between the ages of 0-12 who 
present for treatment and have guardians present for consent will be treated. 
 
7.3 Monitoring Mass Treatment Coverage 
 
 The census data that are obtained and updated yearly will be the primary tool used for 
monitoring mass treatment coverage. The programs that are built for data entry of the census data 
will have a report that will be generated, consisting of mass treatment lists for each community. 
These master lists are used to record observed treatment coverage for each resident of the 
community. The data entry of these lists is essential to monitoring coverage as the treatment is 
underway.  
 
After each community has completed its mass treatment, the treatment data set is sent to the 
principal investigator within a week in order to monitor the success of the treatment team in 
reaching coverage targets. S/he will review the percent coverage of the community, and if it is over 
or under target, the reasons why in the file. This will be done within three weeks of mass treatment 
ending so that if necessary, the treatment team can be re-deployed to the community to improve 
coverage. If all residents are accounted for, and the resident did not meet treatment coverage targets, 
the principal investigator will discuss with the treatment team supervisor ways to improve coverage 
for the second or third rounds (perhaps different timing or working with other community health 
team members, for example).        
 
7.3.1 Mass Treatment Verification Procedure 
Treatment verification is critical to ensuring that coverage levels have been achieved and that 
reported data is accurate.  Treatment verification occurs after each community has completed mass 
treatment and is conducted by the Community Drug Distributers (CDDs) who initially treated the 
villages.  Post-mass treatment, a CDD pair, consisting of a man and a woman for each sub-village, 
returns to the village to randomly select a sample of no less than five houses for interview.  During 
the interview, the CDD pair records the number of people residing in the house and how many of 
those people received treatment on a treatment spot-check form.  After the sample of houses is 
interviewed, the CDD pair compares the information recorded on the spot-check form to the data 
in the census treatment books as well as the information gathered from the household’s respondent 
during team members initial visits to the home prior to mass treatment.     
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7.4 Masking Intervention 
 
These trials are single masked, as it is not possible to mask the communities to the 
assignments they are to receive. There are two outcomes-clinical trachoma and infection-based on 
data collected by the survey teams. The teams that implement mass treatment are different than the 
teams that will be undertaking the survey. The survey team will be unaware of the assignment to 
coverage arm (80% versus 90%), and this element of the trial will be masked to the trachoma 
graders. For villages randomized to target children for treatment, the survey teams are liable to be 
informed of treatment status by families.  
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Chapter 8: Cost Effectiveness Data Collection 
________________________________________________  
 
8.1 Overview  
The cost effectiveness analysis will be based on community cost estimates that we will 
calculate using cost collection instruments.  For each community, we will collect cost information 
regarding: all medical and non-medical personnel involved in the study and all consumables used. 
We will also include laboratory costs attributable to screening/treating each community. The totality 
of the equipment costs - such as vehicles and field equipment costs – and laboratory costs will be 
recorded aggregately and then allocated to each community according to the community population. 
 
For each intervention, a designated member of the team will fill out the recurrent costs 
forms. Equally, this designated member of the team will be in charge of filling out the capital costs 
that are only incurred once for resources shared across different communities. 
 
The filled forms will be double entered using the data entry software “Access” by two 
different data entry clerks. The double-entered data will be verified, and any differences in data entry 
will be checked against the paper forms.  
 
8.2 Cost Data Collection  
 
Cost data to be collected are of two types: 1.Recurrent costs and 2.Capital costs (i.e. those only 
incurred once). The first kind of data will be recorded each day in the field. The second type of cost 
data will be recorded aggregately for the study and allocated to each community according to its 
relative population.   
 
The cost data collection will be done by filling out the following five forms.   
 
 Form 0: Capital Costs 
 Form 1: Medical Personnel Costs 
 Form 2: Non-Medical Personnel Costs 
 Form 3: Field Consumables’ Costs 
 Form 4: Lab Costs 
Chapter 
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Chapter 9: Study Instruments 
______________________________________________ 
9.1 Overview 
 
The data to be collected for this study consists of household information, clinical, and 
laboratory information for each child.  In addition, data are collected on the mass treatment 
intervention and details of the study process. In the next section, we describe the forms that are 
used to collect these data.  
 
9.2 Census Forms  
  
The baseline census form is used to collect information on each household in the 
communities randomized to this trial. It is the central document that provides information for the 
following: 
  
 Selection of households with eligible children in the community 
 Selection of children within a household when there is more than one eligible child 
 Master List for Surveys 
 Data base for mass treatment 
 Environmental factors at the household level that may be important for trachoma 
 
A household (concession/compound in Niger) is a family unit sleeping regularly under the 
same roof.  The definition of resident in the household means a person who has slept in this 
household for at least three months in the past (or if age less than 3 months, was born into the 
household) or who intends to reside with the family for the next six months. In this section, details 
are provided on filling in the Baseline and Update Census forms.  
 
9.2.1 Baseline Census Form  
 
Identification numbers:  
 
      VILLAGE: __ ___ 
 
 In Niger, use the first numeric two digit entry code to identify the village. 
 
 HOUSEHOLD NUMBER: ___ ___ ___ 
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 Use this three digit alphanumeric entry to uniquely identify a household; this number is also 
written on the door of the household.  
 
Village Name: write in the name of the village  
 
Name of head of Household: Write in the name of the head of the household. This may be 
provided by the neighborhood leader or another neighbor if the head or another adult in the family 
is not home.  
 
Census taker: insert the initials of the census taker for this household. Each census taker should 
have a unique set of initials, including a number if there is more than one person with the same 
initials.        
 
Date: insert the date in which the household was completely censused (or the date at which 
census gathering had to be stopped and no information was provided). Use DD/MM/YY format. 
 
1. Is there an adult home to answer questions? 
 
If yes, mark “yes”. If not, the census taker should determine when would be a better time to 
return to get the information. If the family is traveling and not returning during the time of the 
census, then the census taker must indicate the reason for being unable to census. If there is not 
information on the family, s/he MUST return at least three times at different times over the course 
of the village census to try and catch an adult at home. If the census taker is unsuccessful, then mark 
“no” unable to census and provide a reason why. This household will not be chosen as a source of 
sentinel children, as detailed information will not be available on the children, but census 
information may be provided at the time of mass treatment, if the family returns for that activity. 
 
2. How many years of education has the head of household completed?  
 
Ask the question of the adult, and make sure that the answer is years completed, not 
including starting but not completed. Write in the number of years. If the answer is a grade, translate 
that into years completed. If the adult does not know, write letter “X” for unknown.  
 
3. How far away is the nearest water source? 
 
We will measure the distance to water by asking how long it takes to walk one way directly to 
the nearest source of water. Time will be measured relative to the time it takes to do common tasks, 
such as boil water, cook rice, or other tasks. Once the persons can provide an estimate, code as less 
than 30 minutes, 30 minutes to one hour, or more than one hour.  
 
4. Has there been a health education program to promote face washing in this village in the 
last year? I do not mean a radio campaign but a local program in your village. 
 
This is an optional question for areas in which the full SAFE strategy has been implemented. 
It helps determine if the health education campaigns have reached the village level.  
 
5. OBSERVE: Does this household have a latrine:  
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The census taker will look in the compound or area around the house for a latrine. If one is 
not visible, the census taker will ask the interviewee if the household has a latrine. If yes, the team 
member will ask to see it. If it is within 60 feet (20m) of the house, it will be counted as a latrine for 
that household. 
 
6. OBSERVE: Is the doorway area clear of garbage or waste?  
The census taker observes the cleanliness around the doorway of the house. S/he will be 
standardized to observe the area around the doorway for evidence on the ground of leftover food or 
animal or human waste. Waste water or plant detritus does not count as waste. If there is a large 
animal pen within 25 feet (about 8 m) of the doorway, this will be recorded and counted as unclean 
doorway.  
 
7. Household List: note that to the left of each name slot is a pre-printed number in sequential 
order. This two digit code is the unique person code for each person in the household. Use it when 
needed to identify the mothers of children as described below.    
 
Name: List the names of all persons who reside in this household, as defined above. Start 
with the head of household. List the first name, last name, and an optional place for alias if needed.  
Sex: Note the sex of the person as “M” for male and “F” for female.  
 
Date of Birth: If it is possible to obtain a date of birth, record the date of birth: use 
DD/MM/YY format. If only the year is known, fill in “x” for the unknown numbers. Use a 
vaccination card or MCH card if available to get the birthdate of children, and a voting card or other 
piece of ID for the adults if available. If the entire date is unknown, then skip to the column labeled 
“age.” 
 
Age: use this column if no birthdate, or at least year of birth, can be obtained. Use an events 
calendar specific for each region to estimate the age of the person. If necessary, have other family 
members assist in determining the age. Avoid having a consensus using round numbers or last digits 
with 5’s as it indicates digit preference; try to get the person and/or family members to b e as precise 
as possible. For children age less than ten, indicate years and months if possible. For children less than 
age one year, insert a zero for years.  
 
Mom: For each child age less than ten years, insert the two digit person code for the primary 
caretaker of the child. This will help identify the child in subsequent surveys.  
 
Child Face status: The census taker will make observations on the cleanliness status of each 
child ages five years and under who are present at the time of the census. S/he will be standardized to 
measure a clean face as the absence of ocular discharge or “sleep” on the eyelashes or lids, the absence 
of nasal discharge on the nostrils, cheeks, and lips, and the absence of flies on the face when observed 
for 3 seconds. The presence of any one sign is evidence of an unclean face. If the child is not present 
or cannot be observed, indicate “X” for each sign as “don’t know”. Otherwise, record yes or no for 
presence of sign on the child’s face.  
 
Random number: an optional column for study sites where the data entry cannot be 
completed prior to selecting an eligible child in a household, and a random number assignment is 
made in the field. In the field, the census takers will have a Table of random numbers with a random 
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start. They will then go horizontally across the page as they assign each child, starting with the first 
closest to the top, a random number in order that they appear on the table. As the number is assigned, 
it is crossed off the table. The child with the lowest number is the one selected from that household. 
For example, if child 04 has number 54 and child 05 has number 16, child 05 is the selected child. 
Note that if child 05 is not available for the survey, another household entirely is selected, not another 
child from the same household. This avoids always selecting younger children as they tend to be 
around the house.       
 
9.2.2 Census Update Forms 
 
9 . 2 . 2 . 1 :  SUR VEYS  A ND  MAS S  TRE A TM E N T U P DA TE S (F OR M  2 )  
 
 After the baseline census, surveys will be undertaken and mass treatment provided. Each of 
these contacts provides an opportunity to update the census information for the village. The Master 
List of eligible children for the survey has a place to note if the child has died or moved permanently 
from the village. If these are the reasons the child was not examined, then a census update form is 
generated for data entry. Similarly, if a resident has been added to a household at the time of mass 
treatment (who is not a visitor), or a resident has died or moved, this information is noted in the 
mass treatment book and generates a census update form. The Census update asks for the complete 
identifying number of the person. This is the village number, household number and person 
number. Assign the next available number in the household to the person to be added.  
 
If the person is to be added: fill in the information on the new addition exactly as described 
for the baseline census:  
 
Name, Sex, Date of Birth, Age, and Mom are filled out the same as described in Form 1.  
Note for new additions if they are children, the face status is not needed.  
  
If subtracting a person from a house: check that the person whose ID is listed is to be 
subtracted from the household and provide a reason. If the person is known to have moved to 
another household in the village, check #3, and provide the household number where the person 
has moved. If the household number is unknown, provide the name of the head of the household 
and as soon as possible, locate the household number for that head of household. Generate another 
census update form to add those persons to their new household. If the reason for subtraction is not 
death or re-location, check “other” and specify the reason. If the person is in the village but refused 
to be surveyed or mass treated, DO NOT fill in a census update form. This is only to be used if the 
location has changed.  
  
If subtracting an entire household from the census, you do not need to insert a person 
number, but item #3 on change code must be checked. Provide a reason for the subtraction. The 
result will be the elimination of that household number, so if the entire household has become part 
of another household (reason #2) then be sure and have the number of the other household, and 
add the persons to the household with another census update form.       
 
9 . 2 . 2 . 2  YE ARL Y CE NSU S  U PDA TE S (F OR M  3 )  
 
 The census will be updated every year in preparation for drawing a new sample, and 
undertaking mass treatment. A Master Census list of each house will be printed, using the most 
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recent census update data, likely from the six month survey previous. The census takers will use this 
book to return to each house and update the census.  
  
If adding new persons, use the same information as in the baseline census form:  
 
Name, Sex, Date of Birth, Age, and Mom are filled out the same as described in Form 1. 
 
If subtracting a person, indicate the reason as described above: If the person is known to 
have moved to another household in the village, check #3, and provide the household number 
where the person has moved. If the household number is unknown, provide the name of the head 
of the household and as soon as possible, locate the household number for that head of household. 
Generate another census update form to add those persons to their new household. If the reason 
for subtraction is not death or re-location, check “other” and specify the reason. 
 
If the entire household has departed the village, then note the household has left 
permanently. There should be tangible evidence of permanent re-location and not just traveling. 
Temporary absences of households of less than one year should not be changed in the census unless 
the neighbors/village leaders know they have gone for good.   
 
In the event that a new household has come into the village, then the census taker should 
assign a new household ID (use the next available household number on the village list being certain 
that it has not been assigned elsewhere). Add the number to the doorway. Fill in a census form 
identical to the baseline census form with household information noted as described above.    
 
9.2.3 Master List of Eligible Children for Survey  
 
As the examination surveys are undertaken, the intake clerk will have a master list of children 
who have been randomly selected for the surveys (Form 4). On the list is a column that allows 
reasons to be given for why children are not examined. If a child is not examined due to death or a 
permanent move out of the village, then a census update form is generated by the intake clerk, and 
that form is entered into the census data base and updates the census files.        
 
9.3 Ocular Form 
  
The top of the ocular form (Form 5) is pre-printed with information from the census data 
base. There should also be affixed a set of four labels. These labels are used for the specimen vial, 
the specimen log book, and the photolog book if necessary and the field control swab if necessary. 
The examiner should observe the form for a star in the upper right corner, which indicates the child 
needs an ocular photograph of the right eye.   
 
Child Study ID number: the nine digit code consists of a two digit village code, followed by 
the household number followed by the person code.  
 
Examiner: the person who will be doing the trachoma grading should insert initials. These 
initials will be checked against a data base of certified graders.  
 
Date: the date the exam was performed should be written in. The format is 
DD/MM/YYYY. 
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Child’s name, Age, and Sex: as it appears in the census database will be printed here.  
 
Head of Household name: the name of the head of the household where the child resides is 
listed here as it appears in the census data base.  
 
(NOTE: The age and sex help identify the child that should be examined, in case there is any 
confusion. The head of the household name is useful to locate the child or perform a house 
visit if necessary) 
 
1. Was the ocular exam performed on the child?  
The appropriate box is checked. If the child was present but no exam was done, a reason 
should be specified. If answers 2-5 are checked, then the first child off the alternate list 
should be informed and brought in for examination. If answers 4 or 5 were checked, then a 
census update form also needs to be filled out to ensure the census data base is updated.      
 
2. Classification of trachoma 
The examiner first examines the LEFT EYE. S/he grades the eye for trichiasis and corneal 
opacity. The eyelid is then flipped and signs of TF, TI, and TS are graded as present: “1” or 
absent: “0”. If they cannot be graded at all, use grade “9” for cannot grade.  
The examiner then examines the RIGHT eye. The grading is repeated. The examiner inserts 
“0” or “1” as necessary. No space should be left blank-if the sign is not present, a “0” must 
be written to be certain the sign was not skipped.  
 
3. Was a swab taken? 
A swab must be taken of the eyelid of the right eye (if the child is selected for photography, 
then the image is taken prior to swabbing). If yes, then the examiner must write in the box 
number in which the vial is placed, and place an ID label next to the box number. The label 
helps to make certain the vials are not mixed up. If the swab is not taken a reason must be 
provided, and a child from the alternate list is informed and brought in for examination.  
 
4. Was this child chosen for photography?  
If yes, then tick off the yes box and place the ID label next to the yes box and another label 
in the photography log book. The first image taken is of this identification number in the 
photography log book.  
 
5. Was this child chosen for a field control lab swab? 
If a blue colored swab was selected for this child, then the child is to have an air swab taken. 
In this case, a special set of field labels have been created which resemble regular 
identification numbers but are laboratory controls. Place one of these triplicate labels next to 
the yes box, to link the child to the field control; place the second label on the vial, and place 
the third on the specimen shipping list for the box in which it will be inserted.           
 
9.4 Photolog Book 
  
The purpose of the photolog book (Form 6) is to keep a record of the photograph images 
taken as back up in case there is an error in the order the images are taken, or the ID photo is 
missing. The photolog book consists of sequentially numbered columns. For each person to be 
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photographed, the ID label with the form is placed in the next available slot, and the image is taken 
of that identification number. This link enables the clinical grade to be associated with the 
photograph grade. Then the photographer takes two images of the upper eye lid.  S/he reviews the 
images, and if they are acceptable, crosses off the next two slots after the ID label in the photolog. If 
one or both is not acceptable, then one or more are deleted and new images taken until there are at 
least two that are acceptable for transmittal. There should be an “x” for as many images as are going 
to be transmitted.  
 
 At the end of the survey, the photographer burns the 150 plus images (50 children times a 
minimum of three images) onto a CD and sends the CD to Dr Bailey at LSHTM, with a copy of the 
photolog for that survey period.        
 
9.5 Ocular Specimen Shipping List  
  
Each of the specimens taken will be placed in a box for the laboratory that holds 100 tubes. 
The boxes are numbered sequentially, and indicate the village and date it is filled. As the specimens 
are taken, a label is placed on the ocular form, on the vial, and on the shipping list. Each page of the 
shipping list (Form 7) refers to a separate box, so that each page can serve as the list sent with the 
specimens to the lab to describe the contents of the box. In addition, the box number is indicated 
on the ocular form, so if a tube is missing, the likely box in which it was packed can be located.  
  
When the page for a box is completed, the page is copied to send with the box when 
shipped. And the original is kept with the field team as a record of having taken and packed the vial.    
 
9.6 Mass Treatment Log Book  
  
This book (Form 8) is printed out from the census data base at the time of mass treatment, 
for use by the mass treatment team to determine coverage. Each page is a unique household in the 
community, organized by village and last name of the head of household. Section I is the listing of 
the current residents. For each person, indicate with a tic in the appropriate box if they were treated 
or not, and if not present, why they were not present. If they were treated, then indicate the dose 
that was provided in terms of number of pills or ml of liquid.  
  
Section II permits adding new residents and indicating if they are temporary residents of the 
household for the purposes of mass treatment. Sometimes the village is inflated with persons who 
want treatment, and indicate they are part of a household in case that is a requirement, which in this 
study it is not for purposes of mass treatment. By adding them and indicating they may be just 
temporary, it helps account for the doses used but does not artificially inflate the census or coverage 
figures.  
  
This book is entered into the data base as a record of coverage for the community, and if 
new persons have come into the house as permanent residents, then the census is also updated.  
    
9.7 Cost  
 
Form 0: Capital Costs 
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This form contains cost information on any vehicle used during the study and field costs 
incurred only once. This table will be filled out only once and not for every field trip. Capital costs 
will be imputed to each village on a population based proportional basis at the end of the study. 
 
The table referring to capital costs for vehicles: 
 
1. Average petrol cost per kilometer/miles: Record the cost of petrol, in local currency, at the 
beginning and end of the field trial. Add these 2 values together and divide by 2 to get the 
average cost. Conversions into US$ will be performed at the end of the study. 
2. State whether the car was bought or rented 
3. State the purchase price, in local currency, when applicable. 
4. State the daily cost, in local currency, of the vehicle if it is rented 
5. State the years of useful life attributable to the car. This will be calculated based on the year 
of make of the car and the number of kilometers ran by the car. 
6. State the resale value of the vehicle (if it is not resold at the end of the study, state what the 
likely resale value would be). 
 
The table referring to field equipment capital costs: 
For each item of equipment: 
 
1. The number of units 
2. The price/unit in local currency 
3. State whether the good was donated or purchased 
4. If the good is donated, state what its market value would be. 
 
Form 1: Medical Personnel Costs 
Form 1 will be filled out for every day in the field.  
 
At the top of the form: 
 
1. The date of fieldwork will be recorded in the format: “1st January 2008.”  
2. The location(s) of fieldwork (the name of the community/communities worked in)  
3. The activity/activities performed that day (e.g. sensitization, census, examination, treatment) 
4. State clearly the number of people covered by the activity e.g. “100 children examined”, “150 
people treated”. 
5. The distance traveled (state km or miles) that day by each vehicle separately 
 
Medical personnel table: 
 
1. The position of the medical personnel involved (e.g., ophthalmic nurses). Each person is 
written on a separate row 
2. The number of hours spent working that day (including travel to and from location from 
accommodation) 
3. The tasks performed that day by that person 
4. The person’s normal salary and the over what time unit (e.g. salary/year), in local currency 
5. If, and how much (in local currency), the person received as a per diem 
6. Any additional costs for that person (e.g. accommodation, food etc.). 
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7. Any notes that are relevant to understand the extent of the involvement of that person in the 
study. 
 
Form 2: Non- Medical Personnel Costs 
Form 2 will be filled out for every day in the field.  
 
At the top of the form: 
 
1. The date of fieldwork will be recorded in the format: “1st January 2008.” 
2. The location(s) of fieldwork (the name of the community/communities worked in)  
3. The activity/activities performed that day (e.g. sensitization, census, examination, treatment) 
4. State clearly the number of people covered by the activity e.g. “100 children examined”, “150 
people treated.” 
5. The distance traveled (state km or miles) that day by each vehicle separately 
 
Non-medical personnel table: 
 
1. The position of the non-medical personnel involved (local helpers, drivers, etc). Each person 
is written on a separate row 
2. The number of hours spent working that day (including travel to and from location from 
accommodation) 
3. The tasks performed that day by that person 
4. The person’s normal salary and the over what time unit (e.g. salary/year), in local currency 
5. If , and how much (in local currency), the person received as a per diem 
6. Any additional costs for that person (e.g. accommodation, food etc.) 
7. Any notes that are relevant to understand the extent of the involvement of that person in the 
study. 
 
Form 3: Field Consumables Costs 
Form 3 will be filled out for every day in the field.  
 
At the top of the form: 
 
1. The date of fieldwork will be recorded in the format: “1st January 2008.”  
2. The location(s) of fieldwork (the name of the community/communities worked in)  
3. The activity/activities performed that day (e.g. sensitization, census, examination, treatment) 
4. State clearly the number of people covered by the activity e.g. “100 children examined”, “150 
people treated” 
5. The distance traveled (state km or miles) that day by each vehicle separately 
 
Field consumables table: 
 
1. The name of the consumable (one consumable per row). These items may include: tables, 
powder, water if bought, dispensing instruments, swabs, gloves, etc. Note that vehicle repairs 
are recorded here. 
2. The cost/unit (in local currency), plus specify what the unit is e.g. “Box of 100 gloves”, “Box 
of 100 swabs” 
3. How many units were used  
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4. State whether the goods were donated or purchased  
5. If the good is donated, state what its market value would be 
6. Any relevant notes that can clarify the market value attributed to the good when 
controversial. 
 
Form 4: Lab Costs for PCR 
Form 4 will be filled out for every day of PCR lab work. 
 
Capital costs table: 
 
For each item of equipment (e.g. freezer, refrigerator, thermocycler, safety cabinet, pipettes, heating 
blocks, vortex, tube racks, plate washer, incubator, Microwell Reader, computer, printer): 
 
1. The number of units bought 
2. The price/unit in the currency in which they were bought 
3. State whether the good was donated or purchased 
4. If the good is donated, state what its market value would be 
 
Lab staff costs table: 
To be filled in every day: 
 
1. The position of the lab staff member (e.g. lab technician). Each person is written on a 
separate row 
2. The number of hours spent working that day on the study’s samples - excluding the lunch 
break if it lasts more than half an hour 
3. The tasks performed that day by that person for PCR of the study’s samples 
4. The person’s normal salary and the over what time unit (e.g. salary/year), in local currency 
5. Any additional costs (accommodation, food, per diem) per day 
6. Any notes that are relevant to understand the extent of the involvement of that person in the 
study. 
 
Lab consumables costs table: 
 
1. The name of the consumable (one consumable per row). These items may include: tips, 
gloves, tubes, kits, labels, plate lids etc.) 
2. The cost/unit (in local currency), plus specify what the unit is e.g. “Box of 100 gloves”, “Box 
of 100 P200 tips” 
3. How many units were used  
4. State whether the goods were donated or purchased  
5. If the good is donated, state what its market value would be. 
6. Any relevant notes that can help clarify the market value attributed to the good in question. 
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Chapter 10: Training and Certification 
_______________________________________________________ 
  
 
10.1 Trachoma Grading 
 
 The standard for this trial will be the World Health Organization simplified grading scheme, 
consisting of follicular trachoma (TF), trachoma intense (TI), and trachomatous scarring (TS).  Field 
experience consists of graders observing eyelids together and agreeing on the grade, followed by one 
on one with Dr. Lietman, Keenan, and/or Gaynor, discussing eye lids clinical signs. When trachoma 
graders are sufficiently standardized, then we will have a formal trial, where 50 children are all 
graded by each grader, masked to the grades of the others.  At the end, the score sheets are entered 
and kappa assessed for each grader compared to Dr Bailey.  
  
If the kappa is 0.6 or greater, then the grader is certified for the trial. If the kappa is worse, 
then the grader must do more training to achieve a better agreement. No grader can be part of the 
data collection for the trial unless certified.          
  
If, during the course of the trial itself, the review of photographs indicates that a grader is 
drifting, and the kappa for his clinical grades against his photogrades as read by Dr Bailey is less than 
0.6, then the grader receives suspension of certification subject to re-training. The re-training can be 
done in country by another grader who is still certified. Once that grader and the suspended grader 
have carried out a trial in masked fashion, and agree with kappa =0.6, then the suspended grader can 
be reinstated provisionally. At the next clinical grading session, he must be certified again by Dr 
Bailey’s review of the grades of the photographs compared to the clinical grades.  
     
10.2 Laboratory Specimen Handling 
  
The standard for this trial are the protocols developed and used by UCSF.  During the 
standardization workshop, Dr Lietman’s team will conduct training on appropriate laboratory 
procedures. A session where the protocol is described and details provided will be held. This will be 
followed by a field session where those who will be taking specimens will be observed for proper 
technique, from opening the packages, swabbing the eyelid and inserting the swab in the vial, and 
labeling. Open discussion of technique will take place for the first and possibly second attempts. The 
lab technician will need to perform properly on two eyelids to be certified for the trial. No lab 
technician can be part of the data collection for the trial unless certified.  
  
Throughout the trial, air swabs are taken to check for possible field contamination. If any of 
the swabs are positive, then the lab technician receives provisionally certification, subject to review 
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by another, certified, lab technician in country. Once re-training is accomplished, the lab technician 
is re-certified, subject to review again of his field control swabs.  
   
10.3 Photography 
  
Each person who will be doing photography for the trial will receive training from Drs 
Bruce Gaynor, Tom Lietman, or Jeremy Keenan on the proper use of the handheld Nikon D series 
with macro lens to achieve gradable images of the upper lid. Training will consist of orientation to 
the camera, its parts, and care of the camera. Procedures will be taught that include shooting the 
identification number first, labeling the photolog with the patient identification number, and 
downloading and storing images on a CD for transmittal to Dr Bailey AND to the study site 
investigator.  
 
Participants will practice shooting images of each other’s eyelids until acceptable images are 
obtained, while shooting within a few seconds. Once the trainers feel the photographers are 
sufficiently ready, they will take their equipment to the field and while the trachoma 
graders/laboratory technicians are practicing in their sessions with trachoma cases, the 
photographers will shoot images. (In the event that the photographer is the same person as the lab 
tech or trachoma grader, then the photographer will practice on his/her own cases). 
 
Certification will be granted once photographers pass an oral test on camera care, trouble 
shooting, and procedure, and can submit three consecutive acceptable photographs, with ID 
numbers, from the field, downloaded onto a CD.  Photographers who do not pass this certification 
cannot be used in the trial.  
      
10.4 Study Forms 
 
The standardization workshop will include a session on the study forms which will include 
practice session with other team members posing as head of households for census, and practice 
with census updates, mass treatment, and examination forms.  
 
In the field, those who are doing trachoma grading will practice filling in the ocular forms, 
the cost forms, and the mass treatment forms. Those supervising census will practice on households 
in the village with census forms and updates. Standardization exercises on observations of a clean 
face, presence of a latrine, and observations of garbage and waste around the doorway will also be 
done. The team leaders will be expected to teach their census teams these observations once they 
have been standardized at the workshop.  
 
10.5 Data entry 
 
 Data entry personnel will be trained  on study forms, to understand details on the content 
and completion requirements for the forms. They will then attend sessions on data entry programs 
for the study that will cover the following topics:  
 
 How to maneuver through the data bases 
 How to do data entry for each form 
 Double data entry 
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 How to troubleshoot problem forms 
 When to send forms back to the field for resolution  
 Meaning of error messages and warnings 
 Saving data bases 
 Copying data bases for back up and encryption  
 Printing reports 
 Signing off and proper storage of paper forms  
 Tips on Access 
 
The data bases will have a manual associated with them for use by the statisticians and data 
managers. 
  
The data managers must be certified by Mr Dreger, lead programmer for JHU, on data entry 
of all forms. Certification will consist of successful entry of a set of practice forms, saving and 
copying data bases, and proper sign off on forms. Once certified, the data manager can then train 
their data entry team members. All certified data entry team members must have their names sent to 
the study site investigators and the Executive committee members.  Only data entry persons who 
have been trained and certified will be permitted to do data entry for this study, and their initials will 
be recognized for data entry.  
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Chapter 11: Data Management and Routine Reports 
_______________________________________________________ 
 
11.1 Overview 
 
To ensure appropriate data management, one person must be responsible for the 
supervision of data collection, processing, and storage.  The study coordinator will be responsible 
for the supervision of data collection at the field sites during baseline and subsequent follow-up 
visits.  Once the team has finished the field work in a community, the study coordinator will 
supervise data entry and management at the central office in each study site. The study coordinator 
will have ultimate responsibility for regularly checking with each individual to evaluate data flow.  
 
All study forms were created in English and they will be translated to the local languages if 
needed. The process of translating forms is a multi-stage process that requires a minimum of two 
individuals fluent in both English and the local language.  One individual will translate all forms into 
the local language.  Once the translation is complete, the forms will then be given to a second 
translator who will translate the forms back into English.  Both translators will review the forms for 
cultural sensitivity and understanding, and will report any problems to the principal investigator.  
The newly translated English-language forms will then be compared to the original forms to 
determine any differences that arose during the translation process.  If corrections need to be made, 
the principal investigator will meet with the first translator to discuss how the differences arose and 
what changes need to be made to correct these differences.  The first translator will then make the 
changes to the local language forms and give them to the second translator, who will again translate 
the forms into English.  This process will continue until all participants in the translation process are 
satisfied that the local language and English language forms are interpreted in the same manner.    
 
11.2.1 Study Forms Preparation 
 
1 1 . 2 . 1 . 1  CEN SUS  FO RM S  
  
At baseline, each census taker is given a set of forms for a village, and a list of household 
numbers unique to them. The numbers may begin with a unique letter, then sequential numbers. At 
subsequent census, a master Census Book is created with the most recent version of the census for 
that village, which is used to update the census with new arrivals and departures.   
  
1 1 . 2 . 1 . 2  M AS TER  SUR VEY L IS T    
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An electronic copy of the original census document is an electronic copy of the original 
census document.  Using an electronic copy of the census, 120 children are randomly chosen.  These 
children are listed on a Master Survey List, containing the full spelling of each individual’s name, as 
well as their age, gender, and household number.  A new Master Survey List is generated for each 
village at each collection visit and is used for both mobilization (the day before collection is 
scheduled) and registration. 
  
1 1 . 2 . 1 . 3 OCU LAR  EX AM INA TION  F OR M 
  
 The Examination Form is printed for each of the 120 children who will be part of the 
sample survey in each village. Labels are also pre-printed for placing on tubes, photolog books, and 
specimen shipping log books.  
 
1 1 . 2 . 1 . 4  BL AN K CE NSU S U PDA TE  FO RM S  
  
 Blank forms are brought each day to the field during surveys or mass treatment in case they 
are needed to update information on sample children or residents.    
 
11.2.2 Daily Data Management Activities in Field 
 
 All completed Master Survey Lists, Census update forms, Ocular Examination Forms and, 
depending on the activity, mass Treatment or Census books will be given to the Study Coordinator 
at the end of each workday and stored in a safe, secure place for transport at the visit’s conclusion. 
The Study Coordinator will check the forms for completeness and accuracy.   
 
11.2.3 Data Entry 
 
The treatment data collected in the field will be entered into a database at PNLCC in 
Niamey.  A double entry on key fields, using the uniform Access data entry package created for each 
site, will be done to minimize data entry errors.  The study coordinator will do the final editing.  The 
collection fieldwork data will be entered into a database by Proctor Foundation’s Database Manager, 
who will also oversee the work of the staff member helping to double-enter the data. The Proctor 
Database Manager will also enter all PCR results into the database. 
 
11.2.4 Preparation of Data For Transfer To UCSF 
 
1 1 . 2 . 4 . 1  DA TA MAN AG EM E N T 
 
All treatment and collection data will be entered within four working weeks of collection.  
Data will be entered and inconsistencies will be resolved by the respective study coordinator or, if 
necessary, by consultation with the appropriate data collector.  Access to any patient information 
will be protected by a password, or locked in a secure storage room.  All data will be backed up 
upon entry, and forms will be kept until the conclusion of the study. 
 
1 1 . 2 . 4 . 2  RECO NC IL IA TIO N  O F DA TA   
Before data entry, the forms will be reviewed and cross-checked for consistency and 
completeness.  If the forms are not filled out completely, the Study Coordinator will contact the 
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person responsible for completing the form to provide missing data or clarify any inconsistent data.  
The Study Coordinator is the only person who is authorized to add missing data or make any 
changes to the study forms.  All changes will be made in a different color ink and initialed and dated. 
 
1 1 . 2 . 4 . 3  S PEC IMEN  TRA N S FER  PR OCE DURE S   
In accordance with the Roche COBAS AMPLICOR™ CT/NG protocol, swab samples 
taken in the field will be transported on ice in a closed, insulated container until arrival in San 
Francisco, where they will be stored at -80°C for later analysis.  Samples will be imported in the USA 
as per the CDC Permit to Import/Transfer Etiological Agents or Vectors of Human Disease. 
 
11.2.5 Preparation of Data For Transfer To LSHTM 
 
Two separate data entry clerks at PNLCC in Niger will double enter cost-effectiveness data 
using the Access program.  The double-entered data will be verified, and any differences in data 
entry will be checked against the paper forms.  The study coordinator will send the draft dataset to 
Proctor for verification. After reviewing the dataset with the Proctor Database Manager, the Proctor 
study coordinator will transfer the final dataset to the representative at LSHTM.  
 
11.2.6 Data Editing At the Coordinating Center  
 
Through range checks, the data entry software ensures to a large extent that there are no 
inconsistencies or invalid collection data.  Data will also be checked by the Database Manager for 
consistency and errors. 
 
The treatment data collected in the field will be entered into a database at PNLCC.  A 
double entry will be done to minimize data entry errors.  The study coordinator will do the final 
editing.  The collection fieldwork data will be entered into a database by Proctor Foundation’s 
Database Manager, who will also oversee the work of the staff member helping to double-enter the 
data. The Proctor Database Manager will also enter all PCR results into the database. 
 
11.2.7 Data Management Process 
 
All completed Census Forms, Master Lists, Ocular Examination Forms, and Treatment 
Forms will be given to the PNLCC Study Coordinator at the end of each workday and stored in a 
safe, secure place for transport.  The Study Coordinator will check the forms for completeness and 
accuracy.   
 
 Master List and Census Forms:  Forms have patient information/names and will be 
organized by the PNLCC Study Coordinator and stay in Niger, stored in secure, locked area.   
 Ocular Examination forms:  Should be immediately photocopied, with one copy stored with 
PNLCC, and the other transported to the Proctor Foundation for double data entry under 
supervision of the Data Management Specialist.   
 Treatment forms:  Treatment coverage calculated and recorded, forms organized and stored 
in secure place at PNLCC office in Niamey. 
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11.2.8 Periodic Reports 
 
PNLCC/Proctor Study Coordinators will deliver periodic reports updating partners on each 
collection and treatment visit.  Reports will be deliverable within 60 days of completion of the visit.  
 
11.2.9 PCR Result Reports 
 
All PCR results will be double-entered at Proctor within one week of obtaining results.  Any 
inconsistencies will be resolved by the appropriate study coordinator (PNLCC or Proctor), and if 
necessary, by consultation with the appropriate examiner or lab personnel.  Patient names will not be 
made available to UCSF personnel; individuals will be identified by ID number only.  All data will be 
backed up upon entry, and forms will be kept in locked cabinets through the conclusion of the 
study.   
 
11.2.10 Data Storage 
 
At the data-coordinating center, the operator takes a backup copy of the day’s entry onto the 
data server and a CD.  The data in the main computer will be backed-up daily and there will be at 
least two sets of backup disks at any particular time.  All the backup CDs will be kept in a place 
different from the computer center. 
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Chapter 12: Quality Assurance Policies and Procedures 
______________________________________________________________ 
12.1 Overview 
Several policies and procedures are built into this project in order to provide assurances of 
quality in the data collection, processing, and management, as well as assuring proper treatment of 
all participants.  General QA procedures include: 
 
 Intensive training sessions: All individuals involved in the study will undergo training and 
certification for all study procedures for which they are responsible.  
 Development of standardized forms and procedures for completion of forms. This includes 
procedures for recovery of missing data and changing responses, if necessary, as described 
below.   
 Monthly data editing, report generation, and reconciliation, with feedback to the clinical sites in 
Niger, and the laboratories by each Data Coordinating Center.  The process of providing 
periodic feedback on missing data or incomplete or out of range data is critical to timely 
recovery, identification of problems, and remedial actions to ensure that problems are solved. 
 Monitoring of quality of trachoma grading and laboratory procedures used in the field, and in 
the laboratory. The Data Coordinating Centers will review the adherence to randomization 
procedures, treatment administered, timely follow-up of villages on schedule, agreement among 
graders for trachoma assessment in collaboration with Dr Bailey, and laboratory evidence of 
contamination of specimen collection or inadequate specimens. If the review uncovers a 
problem, the CC will notify the Study Site Principal Investigator, as well as issue reports to the 
Executive Committee. The clinical sites will immediately institute retraining procedures, 
including suspending a staff member from performance of the task until adequate performance 
can be demonstrated.     
 Within each clinical site, the project directors have planned bi-weekly meetings of the census, 
survey, treatment, and the Data Entry Teams, to review reports and study progress, and address 
problems identified by the Data Coordinating Center. 
 Masking of survey team as much as possible, and certainly the laboratory personnel, to treatment 
randomization. This procedure avoids bias in detection of infection, and determination of 
outcome.  
 Active oversight by the Project Director in the field at the commencement of each study visit. 
The project directors will ensure the next phase of each part of the project proceeds smoothly, 
the data flow is steady, and the feedback for the new phase is in place. 
 Site Monitoring with 6 monthly site visits by the Study Site Principal Investigator. These will 
focus on adherence to protocols, review of team meetings, and resolution of any issues.   
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 Creation of a paper or electronic trail to any data modifications and limiting access to the main 
database. Extensive back up procedures that protect the quality of the database. These 
procedures help ensure the integrity of the database.  
 The Executive Committee will meet every six months to monitor, across sites, study progress, 
address any issues arising from data quality monitoring, review safety reports and review consent 
procedures.  
 
12.2 General Guidelines for Form Completion 
 
A significant component of quality assurance for data collection is the proper completion of 
forms.   The following rules apply when completing the forms:  
 
 Complete forms in “real time”. Do not fill in the forms at a later time, or more convenient time. 
Later completion has a high potential for recall bias, missing data, or wrong data. The form must 
be filled in while the child/family member is present. The most difficult form to accomplish this 
will be the mass treatment form, which may be completed over a period of days for the village. 
However, it is essential that all persons be accounted for in terms of treatment. In the event of 
missing data, the staff must NOT try to recall the missing treatment but re-question the family 
to capture the data. If this cannot be done, it is better to code the data as missing (se below).  
 Use only black ink for initial forms completion 
 Use only red ink for alterations/edits to original entries on forms, which must be initialed by the 
person making the change. 
 Check to make sure that ID labels/data and study identifiers are on every page of every form. 
Forms that do not have this information are to be referred back to the study site project 
directors for clarification and review.  
 Print all written responses 
 Do not change units or re-phrase questions.  
 Enter data in the units and number of digits prescribed on form. Do not record fractions. Use a 
decimal only if it is written on the form.  Be sure to include a value behind a decimal point, if 
applicable. 
 Right justify all numbers, entering leading and following zeroes where applicable. 
 Left justify all letter codes, leave remaining spaces blank. 
 Write pertinent comments in the margins or on the last page of the form. 
 Review all responses for completeness, skip patterns and accuracy before signing off on a form. 
 
12.3 Missing Data on Study Forms 
 
 In summary, procedures conclude with the person responsible signing off on missing items 
or forms or vials that all attempts to locate have been undertaken and the item is missing. This form 
is transmitted to the Coordinating Centers in order to update the Master File. 
 
If some data within forms are missing and cannot be obtained when the form is reviewed, then 
an appropriate code is inserted in the empty data field to indicate missing or not applicable. 
 
12.4 Changing Responses on Study Forms 
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In general, responses should not be changed unless there was a transcription error, or the 
discovery of incorrect data by one staff on a form prepared by another. In these cases, the following 
guidelines should be adhered to: 
 
 Preserve the audit trail, so changes can be traced from original response to the changed 
response. Often, this means nothing more than making corrections on the original form. In the case 
of responding to questions raised by the data entry clerks, be certain that the missing data/specimen 
forms are properly filled out and accounting made to site project directors. 
 
 Do not obliterate, erase or white-out incorrect response. To correct a response: draw 1 or 2 lines 
through incorrect response, write correct response next to or about it in red ink, put initials and date 
in the margin by the correction.  
 
12.5 Oversight 
 
The Project Directors at each site will be responsible for overseeing the initiation of all 
phases of data collection.  Thus, together with the study site principal investigators, the project 
directors will be present at the start of each new phase of data collection, specifically the census, 
surveys, mass treatment, and new rounds of each. The Project Director will be responsible for 
ensuring that each type of visit runs smoothly, and will remain onsite until all individuals involved in 
data collection for that visit type are comfortable with the data collection procedures. They will also 
be certain that the Data Entry team follows the procedures for each type of data entry, is operating 
smoothly, and responsibly storing the forms.  
 
 Bi-weekly staff meetings of project staff during census, survey, and will be held to review 
progress in enrollment/follow-up, review outstanding problems with forms or data entry, and 
reconcile reports from the coordinating center. The staff can report field problems, issues in dealing 
with the villages, and other concerns that might arise. All staff can attend, including drivers.  
 
12.6 Adherence to Procedures  
      
 The Data Coordinating Center for each clinical site will monitor adherence to the 
procedures for randomization, mass treatment administered, census and follow-up surveys, 
adherence to standards for trachoma grading and laboratory evidence of contamination of specimen 
collection or inadequate specimens. Mechanisms are in place to ensure that villages are randomized 
to each treatment group in the absence of bias by study staff; and the treatment assignment is not 
known to the laboratory personnel.    
  
12.7 Quality Assurance for Field Trachoma Grading  
 
The images taken will be organized into folders for each examiner by visit. The folders will 
be sent to Dr Robin Bailey for review and grading, as he is the standard to which all the field graders 
have been trained. He will grade each set of 50 digital images for quality of the image, using 2.5 
magnification. The first observation is for grade-ability of the image.  If more than 20% of the 
images are ungradeable for any one photographer, the clinical site will be notified, certification of 
photographer will be suspended and the photographer will have to be re-certified.  
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Dr Bailey will grade each gradable photograph with a clinical grade for trachoma, using the 
WHO simplified grading scheme. The grades will be transmitted to each study site data coordinating 
center, which will compare the grades with the grades assigned to the eyes in the field. Agreement 
will be assessed, and if agreement falls below 0.6 in any month, the reasons for disagreement will be 
discussed, and the set of photographs re-circulated to bring agreement to acceptable levels. If 
necessary, the survey will be interrupted while the study site lead investigator and the field grader re-
grade photographs and undertake field work until agreement is re-established. Some of the 
disagreement could be due to differences between grading photographs and grading live eyes in the 
field, although we have shown very high concordance.  
 
The quality assurance of grading in the field is a required report from each center that will be 
presented at six months to the executive committee for review and reported to the DSMC during 
their annual review.  
 
12.8 Quality Assurance for Specimens 
 
Once per year, a set of five positive and five negative specimens from each laboratory will be 
re-aliquoted and half the sample will be sent to the Proctor laboratory, masked as to the findings 
from the original lab. The Proctor lab will re-run the results, as will the lab of origin for 
confirmation of results, thus providing assurances of similar procedures across laboratories. There 
must be at least 80% concordance of results between the laboratory and the Proctor lab.  
 
The following steps will be followed:  
 Dr Lietman and the lab of origin will send their results to the study site CC.  
 The CC will send a report of the concordance, with ID numbers of non-concordant results, 
to the lab of origin and to Proctor.  
 If concordance is at least 80%, the CC will issue a one year quality assurance certificate to 
the lab, and to Dr Lietman for his records, and to the Executive committee.  
o If concordance is less, the CC will issue a provisional notice to the lab chief and Dr 
Lietman, who must work together to resolve the difference, including  re-sending 
specimens until concordance is reached. Once concordance is reached, the quality 
assurance certificate is again issued to the lab and to Dr Lietman for his records, and 
to the Executive Committee. Note that some of the discrepancy may be due to issues 
with shipping, resulting in loss of positivity of specimens. To the extent possible the 
re-aliquoted specimens in the laboratory will be stored under conditions that mimic 
the shipping and re-storage so that conditions of the specimens are similar.  
 
 The Executive Committee will review yearly the quality assurance certificates for the 
laboratories. Data on continued quality assurance will be presented to the DSMC.    
 
 There is also the possibility of field contamination, which is checked by using the “blue air” 
specimens. Each laboratory will process these controls masked as to their status as controls. The CC 
for each site is responsible for reporting the positivity of the negative field controls to the study site 
investigators. If the rate is above 1%, then the investigators must take remedial action to correct 
field procedures to remove contamination. Data on field contamination results will be presented to 
the DSMC for each site by the CC. 
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Chapter 13: Adverse Events 
________________________________________ 
  
  Azithromycin is being given to these communities under the auspices of the National 
Trachoma Control programs in Niger. They have determined, for programmatic reasons, that 
widespread coverage with azithromycin is an acceptable community risk for the benefit of 
eliminating blinding trachoma. Millions of doses of oral azithromycin have been distributed for 
trachoma, and reports of serious side effects are essentially non-existent.  This may be due in part to 
minimal surveillance.  In fact, where carefully monitored, there were actually fewer GI side effects 
after taking azithromycin compared to topical tetracycline, perhaps because azithromycin treats 
some cases of diarrhea. Azithromycin is generally well-tolerated.  The most common side effects of 
azithromycin and erythromycin are diarrhea or loose stools, nausea, abdominal pain, and vomiting, 
each of which may occur in fewer than one in twenty persons who receive azithromycin.  Rarer side 
effects include abnormal liver function tests, allergic reactions, and nervousness.   
 
 All community residents will be advised to alert the village health worker if they experience, 
within two weeks of mass treatment, a serious adverse event, defined as diarrhea, nausea and 
vomiting for more than two days, hospitalization for any cause, or death in a family member. All 
adverse events will be recorded on a copy of the census list left with the village health worker by the 
mass treatment teams. These events will be reviewed at the next six month survey, and entered into 
the adverse event data base for reporting to the Data and Safety Monitoring Committee.  If, for any 
reason, the village resident needs further care, they will be referred to the nearest health center for 
examination and treatment, and the most appropriate action will be taken to provide immediate care, 
in accordance with the policies in Niger.  
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Chapter 14: Ancillary Studies  
_______________________________________________________________ 
14.1 Risk of Re-emergence: Pediatric Longitudinal Study 
We need a sample which can be followed longitudinally over time to determine how disease 
or infection re-emerges, and the value of multiple exposures to treatment. For this, a longitudinal 
sample of all children is needed. The sample for the trial is a simple cross sectional and thus the 
sample members may change at each round (as they age, or new residents move in, or as a 
consequence of sampling) this sample cannot address the critical questions of infection, trachoma, 
and re-emergence within children by number of years of mass treatment. For this, we propose a 
longitudinal cohort of children in a wider age range, for whom we can follow age and cohort effects. 
The second sample will consist of a longitudinal cohort of children ages nine and younger who will 
consist of all children in communities which are a sub-set of the randomly selected communities. 
For the longitudinal sample, we will randomly select up to three of the communities in each arm in 
which we will follow all children age 0 to 9 years at baseline. This sample will be a maximum of 750 
children per arm, and a minimum of 300 children. Each year we will re-census the population of the 
communities to enroll any new children ages less than nine years. In this way, we can monitor the 
effect of treatment on successive age cohorts who have experienced variable numbers of rounds, 
and coverage, of treatment. They will also be followed up at each visit scheduled for the random 
sample, and exactly the same procedures for trachoma grading and ocular specimens will be used.   
Within each arm, at least one community will have all children ages less than 9 years followed 
longitudinally. These children will also serve as the random sample at baseline of children ages 0-5 
years. 
 
14.2 Cost Effectiveness Study 
The cost effectiveness analysis will be based on community cost estimates that we will 
calculate using the cost collection instruments described below.  For each community, we will collect 
cost information regarding: all medical and non-medical personnel involved in the study and all 
consumables used. We will also include laboratory costs attributable to screening/treating each 
community. The totality of the equipment costs - such as vehicles and field equipment costs – and 
laboratory costs will be recorded aggregately and then allocated to each community according to the 
community population.   
 
14.3 Anthropometry: Niger 
 
In Niger, trained examiners will take anthropometric measurements, including height, 
weight, and mid-upper arm circumference (MUAC), according to WHO guidelines and 
recommendations for each child 5 years of age and under who is already being examined in 
communities randomly selected communities in arms A, B, C, and D from the study. These 
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measurements will be recorded at the 12 month study visit and the 36-month study visit. In each 
community, of children who are randomly selected for trachoma monitoring, 62 children will be 
randomly selected for anthropometry in efforts to obtain 50 children. If there are less than 62 
children in a community, all children will be selected.  
  
A lightweight measuring board will be used to measure the participant’s height to the nearest 0.1cm 
(Shorr measuring board).  The SECA 874 scale will be used to weigh infants and children to the 
nearest 0.1 kg (Seca Corporation, Hanover, MD). Infants and young children can also be weighed 
simultaneously with their parent or guardian by the unique “mother-baby” function (parent or 
guardian is weighed and then the infant or child while held by the parent). Body mass index (BMI) 
will then be calculated later and used to determine the nutritional status of participants as severe 
malnutrition (BMI <15.9kg/m2), moderate malnutrition (BMI = 16-16.9 kg/m2), mild malnutrition 
(BMI =17-18.4kg/m2) and normal (BMI> 18.5kg/m2) (WHO, 1995). The child’s MUAC will be 
measured at the mid-point between the tip of the shoulder and the tip of the elbow, to the nearest 
millimeter using non-stretch MUAC tapes produced for clinical studies by Johns Hopkins University 
and interpreted according to WHO guidelines. Any child with severe acute malnutrition, defined as a 
weight for height Z-score <-3.0, or severe chronic malnutrition, defined as a height for age Z score 
<-3.0 will be referred to a local health clinic for care. All treatment expenses will be paid for by the 
study. 
 
14.4 Blood Collection: Niger 
 
In Niger, all children being examined for anthropometric measurements (as previously described) will also 
receive blood testing. A single finger stick of capillary blood will be collected for a thick blood smear to 
assess for malaria, for hemoglobin testing, and for dried blood spots to be stored for later testing. Blood 
will be collected by a gloved health worker using aseptic technique. Gloves will be changed between each 
patient. The fingerprick or heelstick site will be disinfected using an alcohol swab. Once the alcohol dries, 
the health worker will prick the finger or heel area with a disposable lancet, and subsequently apply 
moderate pressure approximately 1 cm behind the site of the puncture to obtain sufficient drops of blood. 
The lancet will be disposed of in a biohazard waste container. A piece of gauze will be applied to the 
puncture site until bleeding has stopped. A large drop of blood will provide five small spot on FTA cards 
used for malaria monitoring (FTA Elute cards,Whatman, Kent, UK) and several microliters of blood 
absorbed onto six small circular extensions of another type of filter paper (TropBio Pty Ltd, Townsville, 
Queensland, Australia) used for serological testing, labeled with the patient’s random ID number. Both 
blood spot samples will be left to air dry for 5-10 minutes before being placed in separate small storage 
bags. Blood spots will be stored at room temperature in a locked room in the study coordinators’ office. A 
drop of blood will be placed in the center of a labeled glass slide and spread around evenly with a wooden 
stick. The smear will be allowed to air dry, and then fixed in the field using 100% methanol for 30 
seconds. Smears will be transported at room temperature each day to a diagnostic facility in the nearest 
town to the study area (Matameye). Within 24 hours of thick smear collection, the smear will be stained 
with 2% Giemsa stain for 30 minutes, and parasite density will be measured by a masked reader using a 
microscope at the diagnostic facility.  Smears will be stored at room temperature in the study coordinators’ 
office. A portable spectrophotometer (Hemocue, Anglom, Sweden) will be used for hemoglobin testing. 
A cuvette will be introduced into a drop of blood at the fingerprick or heelstick site, and held there until 
completely full. The cuvette will be will be placed in the Hemocue system, and disposed of in an 
appropriate biohazards waste container. In all cases, study subjects will be identified by their study random 
identification number. Any children with any level of malaria parasitemia, or severe anemia, defined as 
P R E T  M A N U A L  O F  O P E R A T I O N S  
PRET MOO Version 6 – 20Noveber2008                                                                                  53 
 
hemoglobin <5 g/dl, will be referred to a local health clinic for care. All treatment expenses will be paid 
for by the study. 
 
 
